Laurent Greillier

9.1k citations

206 papers · 3.0k indexed · 1 hit paper · h-index 28

Oncology top 2%
- Lung Cancer Research Studies 55
- Cancer Immunotherapy and Biomarkers 41
- Colorectal Cancer Treatments and Studies 20
Pulmonary and Respiratory Medicine top 1%
- Lung Cancer Treatments and Mutations 82
- Occupational and environmental lung diseases 49
- Lung Cancer Diagnosis and Treatment 42
- Pleural and Pulmonary Diseases 31
Cancer Research top 10%
- Cancer Genomics and Diagnostics 16
Geriatrics and Gerontology top 5%
Immunology

Co-authors: Fabrice Barlési Pascale Tomasini Céline Mascaux Philippe Astoul C. Doddoli Benjamin Besse M. Souquet-Bressand Arnaud Scherpereel
Cited by: Oncology Pulmonary and Respiratory Medicine Cancer Research
Partner nations: France United States Italy

In The Last Decade

Laurent Greillier

188 papers receiving 2.9k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2022 First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

Peers

Countries citing papers authored by Laurent Greillier

Since Specialization

Citations

This map shows the geographic impact of Laurent Greillier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurent Greillier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurent Greillier more than expected).

Fields of papers citing papers by Laurent Greillier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurent Greillier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurent Greillier. The network helps show where Laurent Greillier may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Laurent Greillier, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Laurent Greillier Line = papers co-authored together Laurent Greillier links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study T. Pierret,Laurent Greillier,Florian Guisier,Catherine Daniel,R. Descourt,Loïck Galland,Olivier Molinier,C. Decroisette,Alexis B. Cortot,Diane Moreau,Laurence Gamé,Marie Wislez,Nicolas Cloarec,Hubert Curcio,Nicolas Delberghe,J. Cadranel,Boris Duchemann,Anne Claire Toffart,C. Chouaïd,J.B. Auliac	2025	0
2	Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial Jordi Remón,Paolo Bironzo,Nicolas Girard,L. Bigay-Gamé,Óscar Juan,Javier de Castro,Noemı́ Reguart,Laurent Greillier,Sophie Cousin,Éric Dansin,Margarita Majem,Reyes Bernabé,Joaquín Mosquera,Marta Díaz,A. Meya,Daniel Alcalá-López,Alicia García‐Sanz,Luisella Righi,Silvia Novello,Benjamin Besse	2025	1
3	MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial Guénaëlle Levallet,Christian Créveuil,Alexandre Léger-Vigot,Solenn Brosseau,Claire Danel,Arnaud Scherpereel,Sylvie Lantuéjoul,Julien Mazières,Laurent Greillier,Clarisse Audigier-Valette,Emmanuel Bergot,Denis Moro‐Sibilot,Olivier Molinier,H. Léna,Isabelle Monnet,Franck Morin,V. Gounant,Gérard Zalcman	2025	1
4	Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN study N. Girard,Florian Guisier,A. Swalduz,Sylvie Van Hulst,E. Pichon,Pernelle Lavaud,Laurent Greillier,Angélica Tiotiu,Anne Madroszyk,Olivier Bylicki,A. Canellas,L. Belmont,M. Zysman,P.-A. Hauss,B. Godbert,C. Audigier-Valette,Coriolan Lebreton,Franck Morin,V. Westeel	2024	2
5	137P Long circulating-free DNA fragments predict early-progression (EP) and progression-free survival (PFS) in advanced carcinoma treated with immune-checkpoint inhibition (ICI): A new biomarker Sébastien Salas,Linh Nguyen-Phuong,Frédéric Ginot,Laurent Greillier,Pascale Tomasini,Audrey Boutonnet,Jean‐Laurent Deville,Fréderic Fina,Sébastien Benzekry	2024	1
6	Standard atezolizumab leads to severe overexposure in real-world patients with lung cancer: How far could we go in extending dosing intervals and saving money? Sophie Marolleau,Alice Mogenet,C. Boéri,Mourad Hamimed,Joseph Ciccolini,Laurent Greillier	2024	2
7	EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers Marco Tagliamento,Marie Morfouace,Charalambos Loizides,Júlio Oliveira,Laurent Greillier,Judith Raimbourg,Anne‐Claire Toffart,Thierry Chatellier,Nicolas Cloarec,Ivana Sullivan,Birutė Brasiūnienė,M. Duruisseaux,Kersti Oselin,Marie-Sophie Robert,C. Fernandes,Arnaud Poncin,Jean‐Yves Blay,Benjamin Besse,Nicolas Girard	2024	6
8	Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort Simon Nannini,Florian Guisier,H. Curcio,Charles Ricordel,Pierre Demontrond,Safa Abdallahoui,Seyyid Baloglu,Laurent Greillier,C. Chouaïd,Roland Schött	2024	2
9	LBA48 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC) Geraldine Goss,Gail Darling,Virginie Westeel,K. Nakagawa,B. Massutí Sureda,Franco Perrone,S-A. McLachlan,Jin Hyoung Kang,Yi‐Long Wu,Anne‐Marie C. Dingemans,R. Dziadziuszko,M. Okada,Laurent Greillier,C. Audigier-Valette,S. Sugawara,Ernest Nadal,A. Catino,Martin R. Stockler,Kai Ding,C. O'Callaghan	2024	17
10	1441P Atezolizumab and bevacizumab (atezo + bev) ± radiotherapy (RT) vs docetaxel (doc) in checkpoint inhibitor (CPI)–experienced metastatic NSCLC (mNSCLC): Results from the phase Ib/II MORPHEUS-lung study François Ghiringhelli,Enriqueta Felip,Alona Zer,Laurent Greillier,Alastair Greystoke,N. Al-Sakaff,H-J. Helms,J. Pintoffl,Sarang Rahalkar,F. Lim,Byoung Chul Cho	2023	4
11	Étude de cohorte évaluant la toxicité cutanée des anticorps bispécifiques anti-EGFR et anti-MET seuls ou en association aux inhibiteurs d’EGFR E. Connell,C. Sarles,E. Pollien,B. Sterling,Nicolas Macagno,B. Demarez,Laurent Greillier,M.‐A. Richard,Nicolás André,S. Monestier,M. Meurer,A. Jeanson,Caroline Gaudy‐Marqueste,Pascale Tomasini,Nausicaa Malissen	2023	0
12	Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors Clémence Demerle,Laurent Gorvel,Marielle Mello,Sonia Pastor,Clara Degos,Ana Zarubica,Fabien Angelis,Frédéric Di Fiore,Jacques A. Nunès,Bernard Malissen,Laurent Greillier,Geoffrey Guittard,Hervé Luche,Fabrice Barlési,Daniel Olive	2023	13
13	1325P Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations James Chih‐Hsin Yang,M. Wang,C-H. Chiu,P-C. Hsu,Paul Mitchell,Chia‐Lun Chang,T.M. Kim,Thomas John,Laurent Greillier,Lyudmila Bazhenova,Enric Carcereny,Alexander I. Spira,Byoung Yong Shim,K.H. Lee,Manuel Cobo,François Ghiringhelli,C. W. Yip,Jie Xiong,Pasi A. Jänne,C. Zhou	2023	7
14	PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients Jordi Remón,Nicolas Girard,Silvia Novello,Javier de Castro,L. Bigay-Gamé,Reyes Bernabé,Laurent Greillier,Joaquín Mosquera,Sophie Cousin,Óscar Juan,Miguel Sampayo,Benjamin Besse	2021	24
15	Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02–15 study) J.B. Auliac,I. Monnet,A. Bizieux,Laurent Greillier,Margaux Geier,L. Falchero,G. Le Garff,R. Lamy,Florian Guisier,Charles Ricordel,C. Chouaïd,A. Vergnenègre	2021	3
16	Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial Guillaume Eberst,Amélie Anota,Arnaud Scherpereel,Julien Mazières,J. Margery,Laurent Greillier,Clarisse Audigier-Valette,Denis Moro‐Sibilot,Olivier Molinier,H. Léna,F. Rivière,I. Monnet,V. Gounant,Henri Janicot,Radj Gervais,C. Locher,Émilie Charton,Franck Morin,Gérard Zalcman,Virginie Westeel	2019	15
17	Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study Daniel Morgensztern,Benjamin Besse,Laurent Greillier,Rafael Santana-Dávila,Neal Ready,Christine L. Hann,Bonnie S. Glisson,Anna F. Farago,Afshin Dowlati,Charles M. Rudin,Sylvestre Le Moulec,Satwant Lally,Sreeni Yalamanchili,Jürgen Wolf,Ramaswamy Govindan,David P. Carbone	2019	229
18	Predictive Factors of Intracranial Response of Immune Checkpoint Inhibitors in Patients with Brain Metastasis from Non-Small Cell Lung Cancer Julien Bermudez,Céline Mascaux,Youssef Trigui,Julie Biemar,Mohamed Boucékine,Laurent Greillier,Fabrice Barlési,Pascale Tomasini	2019	0
19	First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer Camille Travert,Pascale Tomasini,A. Jeanson,Laurent Greillier,Fabrice Barlési	2019	5
20	Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial Federica Grosso,Nicola Steele,Silvia Novello,Anna K. Nowak,Sanjay Popat,Laurent Greillier,Thomas John,Natasha B. Leighl,Martin Reck,Paul Taylor,David Planchard,Jens Benn Sørensen,Mark A. Socinski,Ute von Wangenheim,Arsène Bienvenu Loembé,José Barrueco,Nassim Morsli,Giorgio V. Scagliotti	2017	77

About Laurent Greillier

Laurent Greillier is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Geriatrics and Gerontology, having authored 206 papers that have together received 3.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (82 papers), Lung Cancer Research Studies (55 papers), Occupational and environmental lung diseases (49 papers), Lung Cancer Diagnosis and Treatment (42 papers), Cancer Immunotherapy and Biomarkers (41 papers), Pleural and Pulmonary Diseases (31 papers), Colorectal Cancer Treatments and Studies (20 papers) and Cancer Genomics and Diagnostics (16 papers). The work is most often cited by research in Oncology (1.6k citations), Pulmonary and Respiratory Medicine (1.8k citations) and Cancer Research (238 citations). Laurent Greillier has collaborated with scholars based in France, United States and Italy. Frequent co-authors include Fabrice Barlési, Pascale Tomasini, Céline Mascaux, Philippe Astoul, C. Doddoli, Benjamin Besse, M. Souquet-Bressand, Arnaud Scherpereel, Julien Mazières and Gérard Zalcman.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact